Αποτελέσματα Αναζήτησης
19 Ιουν 2023 · Triple-negative breast cancer (TNBC) is a very heterogeneous and aggressive breast cancer subtype with a high risk of mortality, even if diagnosed early. The mainstay of early-stage breast cancer includes systemic chemotherapy and surgery, with or without radiation therapy.
15 Φεβ 2023 · Rapid clearance of ctDNA during neoadjuvant chemotherapy in early TNBC is associated with a high probability of achieving pCR [76]. In contrast, the detection of ctDNA after completion of neoadjuvant chemotherapy and surgery is associated with a higher rate of recurrence and a poorer prognosis [77].
4 Ιουν 2024 · Our data from this real-world cohort of patients supports the feasibility and tolerability of ddAC as an alternative for q3week AC in a modified KN522 regimen for the neoadjuvant treatment of...
14 Αυγ 2024 · The study aimed to assess the effectiveness and safety of dose-dense AC compared to every 3-week AC in patients with early-stage TNBC undergoing neoadjuvant chemotherapy plus pembrolizumab.
19 Ιουν 2023 · Triple-negative breast cancer (TNBC) is a very heterogeneous and aggressive breast cancer subtype with a high risk of mortality, even if diagnosed early. The mainstay of early-stage breast cancer includes systemic chemotherapy and surgery, with or without radiation therapy.
1 Αυγ 2012 · An evaluation of the combination of a standard chemotherapy (FEC100 followed by docetaxel) with panitumumab as neoadjuvant therapy of operable TNBC was recently reported with a pathological complete response rate of 65% .
20 Αυγ 2022 · Adding pembrolizumab to several chemotherapy regimens (nab-paclitaxel, paclitaxel, or gemcitabine/carboplatin) in KEYNOTE 355 improved PFS and OS in chemo-naive-PDL1+ TNBC patients, defined...
